Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 4,101–4,200 of 15,747
Humoral Response to 2-dose BNT162b2 mRNA COVID-19 Vaccination in Liver Transplant Recipients
Guarino, M., Esposito, I., Portella, G., Cossiga, V., Loperto, I., Tortora, R., Cennamo, M., Capasso, M., Terracciano, D., Lanza, A. G., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.01.012 · Cited by 29
COVID-19 and oral implications: An updated review
Boyapati, R., Dhulipalla, R., Kolaparthy, L., & Bodduru, R. (2021) · Journal of Oral and Maxillofacial Pathology · doi:10.4103/jomfp.jomfp_198_21 · Cited by 38
“revealed the data on preliminary efficacy and safety for both BNT162b2 (Pfizer‐BioNTech) and mRNA‐1273 (Moderna) vaccines.[30] As several billion doses of vaccination need to”
BackgroundHerpes zoster after inactivated SARS‐CoV‐2 vaccine in two healthy young adults
Özdemir, A. K., Kayhan, S., & Çakmak, S. K. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17577 · Cited by 25
Clinicopathological features of cutaneous reactions after mRNA‐based COVID‐19 vaccines
Tihy, M., Menzinger, S., André, R., Laffitte, E., Toutous‐Trellu, L., & Kaya, G. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17633 · Cited by 23
Naturally occurring spike mutations influence the infectivity and immunogenicity of SARS-CoV-2
Peng, Q., Zhou, R., Liu, N., Wang, H., Xu, H., Zhao, M., Yang, D., Au, K., Huang, H., Liu, L., et al. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-022-00924-8 · Cited by 28
Pollock, K. M., Cheeseman, H. M., Szubert, A. J., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3859294 · Cited by 24
Comparative efficacy and safety of COVID-19 vaccines in phase III trials: a network meta-analysis
Wu, X., Xu, K., Zhan, P., Liu, H., Zhang, F., Song, Y., & Lv, T. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-023-08754-3 · Cited by 29
Cheng, C.-J., Lu, C., Chang, Y., Sun, Y., Chu, H., Lee, C., Liu, C.-H., Lin, C.-H., Lu, C.-J., & Li, C. (2021) · Vaccines · doi:10.3390/vaccines9121489 · Cited by 25
“As immunity is gradually building [3], the protective effects would increase over a given period [18,28].”
BackgroundCOVID-19 vaccine decisions: considering the choices and opportunities
Hotez, P. J., Nuzhath, T., Callaghan, T., & Colwell, B. (2021) · Microbes and Infection · doi:10.1016/j.micinf.2021.104811 · Cited by 27
Safety, efficacy, and immunogenicity of COVID-19 vaccines; a systematic review
Asghar, N., Mumtaz, H., Syed, A. A., Eqbal, F., Maharjan, R., Bamboria, A., & Shrestha, M. (2022) · Immunological Medicine · doi:10.1080/25785826.2022.2068331 · Cited by 26
“A study [40] reported fatigue to be the dominant systemic reaction generally.”
BackgroundInfluentialSimón‐Gracia, L., Scodeller, P., Fisher, W. S., Sidorenko, V., Steffes, V. M., Ewert, K. K., Safinya, C. R., & Teesalu, T. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c17961 · Cited by 24
Meyers, J., Windau, A., Schmotzer, C. L., Saade, E., Noguez, J. H., Stempak, L. M., & Zhang, X. S. (2022) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2022.115803 · Cited by 26
“Both the Pfizer-BioNTech and Moderna COVID-19 vaccine encode a prefusion-stabilized, membrane-anchored SARS-CoV-2 full-length spike protein (Baden et al. 2021; Polack et al. 2020), and thus are capable of eliciting anti-RBD, S1, and S2 antibodies.”
MethodRethinking Remdesivir: Synthesis, Antiviral Activity and Pharmacokinetics of Oral Lipid ProdrugsPreprint
Schooley, R. T., Carlin, A. F., Beadle, J. R., Valiaeva, N., Zhang, X.-Q., Clark, A. E., McMillan, R. E., Leibel, S. L., McVicar, R. N., Xie, J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.26.269159 · Cited by 24
Hovd, M. H., Åsberg, A., Munthe, L. A., Heldal, K., Reisæter, A. V., Vaage, J. T., Lund‐Johansen, F., & Midtvedt, K. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102035 · Cited by 24
Ota, N., Itani, M., Aoki, T., Sakurai, A., Fujisawa, T., Okada, Y., Noda, K., Arakawa, Y., Tokuda, S., & Tanikawa, R. (2025) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2025.111223 · Cited by 33
Vigezzi, G. P., Lume, A., Minerva, M., Nizzero, P., Biancardi, A., Gianfredi, V., Odone, A., Signorelli, C., & Moro, M. (2021) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v92is6.12217 · Cited by 24
“These observations are unanimous with those of safety reported in the major clinical trials of Comirnaty® (the rate of systemic symptoms was higher after the second dose) and the first published reports of the national surveillance systems after the start of the immunisation campaign (11, 12, 23, 25-27): reported symp…”
BackgroundResultHumoral response to mRNA ‐based COVID ‐19 vaccine in patients with myeloid malignancies
Mori, A., Onozawa, M., Tsukamoto, S., Ishio, T., Yokoyama, E., Izumiyama, K., Saito, M., Muraki, H., Morioka, M., Teshima, T., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18138 · Cited by 23
Myocarditis following COVID-19 mRNA vaccination
Parmar, K., Mekraksakit, P., Rio‐Pertuz, G. D., Sethi, P., Motes, A., Hughes, M. L., Wischmeyer, J., Carbajal, L., & Sosa, E. A. (2021) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2021.1990743 · Cited by 26
Copaescu, A. M., Duque, J. S. R., & Phillips, E. J. (2022) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2022.03.030 · Cited by 24
“Other delayed reactions may range from those that interestingly mimic the symptoms and signs of COVID-19 disease, such as anosmia, fever, fatigue, headache, and musculoskeletal pain, 24 to 48 hours following a vaccine dose.(12,46) Lymphadenopathy is now a prevalent reactogenic symptom that is more common following the…”
Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies
Crombie, J. L., Sherman, A. C., Cheng, C., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005328 · Cited by 24
Sun, H., Zhang, Y., Wang, J., Su, J., Zhou, D., Yu, X., Xu, Y., & Yang, W. (2023) · Theranostics · doi:10.7150/thno.86466 · Cited by 30
“IVT mRNA therapy has demonstrated impressive advancements in various fields, including viral vaccine development, cancer treatment, and genome editing, highlighting its broad potential in revolutionizing therapeutic interventions [26-28].”
BackgroundIntawong, K., Chariyalertsak, S., Chalom, K., Wonghirundecha, T., Kowatcharakul, W., Ayood, P., Thongprachum, A., Chotirosniramit, N., Noppakun, K., Khwanngern, K., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.11.006 · Cited by 27
Seephetdee, C., Buasri, N., Bhukhai, K., Srisanga, K., Manopwisedjaroen, S., Lertjintanakit, S., Phueakphud, N., Pakiranay, C., Kangwanrangsan, N., Srichatrapimuk, S., et al. (2021) · Vaccines · doi:10.3390/vaccines9050498 · Cited by 26
Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2
Lassaunière, R., Polacek, C., Gram, G. J., Frische, A., Tingstedt, J. L., Krüger, M., Dorner, B. G., Cook, A., Brown, R., Orekov, T., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00419-z · Cited by 26
Abouzid, M., Ahmed, A. A., El‐Sherif, D. M., Alonazi, W. B., Eatmann, A. I., Alshehri, M. M., Saleh, R., Ahmed, M. H., Aziz, I. A., Abdelslam, A. E., et al. (2022) · Vaccines · doi:10.3390/vaccines10081270 · Cited by 27
“S (Janssen/Johnson & Johnson, Leiden, The Netherlands/New Brunswick, NJ, USA), given as a single shot [9]; and BBIBP-CorV (Sinopharm, Beijing, China), administered on a 0/21-28-day schedule [11].”
BackgroundMethodCovid-19 vaccine trials: Ethnic diversity and immunogenicity
Jethwa, H., Wong, R. J., & Abraham, S. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.05.017 · Cited by 25
“3% from white, Hispanic/Latino, black/AfricanAmerican, Hispanic/Latino and Asian backgrounds, respectively [9].”
BackgroundInfluentialGene editing innovations and their applications in cardiomyopathy research
Kyriakopoulou, E., Monnikhof, T., & van Rooij, E. (2023) · Disease Models & Mechanisms · doi:10.1242/dmm.050088 · Cited by 29
A spectrum of cardiac manifestations post Pfizer-BioNTech COVID-19 vaccination
Lee, E. J., Chew, N., Ng, P., et al. (2021) · QJM · doi:10.1093/qjmed/hcab177 · Cited by 24
Viral genome sequencing methods: benefits and pitfalls of current approaches
Jansz, N., & Faulkner, G. J. (2024) · Biochemical Society Transactions · doi:10.1042/bst20231322 · Cited by 31
Zhou, J., Liu, Z., Zhang, G., Xu, W., Xing, L., Lu, L., Wang, Q., & Jiang, S. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28172 · Cited by 26
“1% efficacy(107) and BNT162b2 had 95% efficacy in preventing symptomatic SARS‐CoV‐2 infections.(108) However, the effectiveness of both vaccines against symptomatic disease caused by Omicron dropped to 75.”
BackgroundIbuprofen, other NSAIDs and COVID-19: a narrative review
Laughey, W. F., Lodhi, I., Pennick, G., Smart, L., Sanni, O., Sandhu, S., & Charlesworth, B. R. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01309-7 · Cited by 28
Evaluation of a SARS-CoV-2 Vaccine NVX-CoV2373 in Younger and Older Adults
Formica, N., Mallory, R., Albert, G., Robinson, M., Plested, J. S., Cho, I., Robertson, A., Dubovsky, F., Glenn, G. M., & for the 2019nCoV-101 Study Group (2021) · doi:10.1101/2021.02.26.21252482 · Cited by 111
Cheung, M. W., Dayam, R. M., Shapiro, J. R., Law, J. C., Chao, G. Y. C., Pereira, D. A. S., Goetgebuer, R., Croitoru, D. O., Stempak, J. M., Acheampong, L., et al. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2300190 · Cited by 27
Faliti, C. E., Van, T. T. P., Anam, F. A., Cheedarla, N., Williams, M. E., Mishra, A. K., Usman, S. Y., Woodruff, M. C., Kraker, G., Runnstrom, M. C., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-02010-9 · Cited by 34
“Despite the demonstrated safety and efficacy of SARS-CoV-2 mRNA vaccines in immunocompetent individuals 1,2,13 , a full understanding of their effectiveness in immunocompromised persons is still lacking.”
4BNT162b2 mRNA COVID‐19 vaccine and semen: What do we know?
Olana, S., Mazzilli, R., Salerno, G., et al. (2022) · Andrology · doi:10.1111/andr.13199 · Cited by 24
Specker, C., Aries, P. M., Braun, J., Burmester, G. R., Fischer‐Betz, R., Hasseli, R., Holle, J. U., Hoyer, B. F., Iking‐Konert, C., Krause, A., et al. (2021) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-021-01055-7 · Cited by 28
SARS-CoV-2 before and after Omicron: two different viruses and two different diseases?
Gili, R., & Burioni, R. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04095-6 · Cited by 30
“Furthermore, in a record time during 2020 [5], extremely safe and effective mRNA vaccines against COVID-19 were developed [6, 7].”
BackgroundMaeda, H., Saito, N., Igarashi, A., Ishida, M., Suami, K., Yagiuchi, A., Kimura, Y., Komino, M., Arai, H., Morikawa, T., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac292 · Cited by 24
“Clinical trials of COVID-19 vaccines found high vaccine efficacy [1-3], and observational studies evaluated vaccine effectiveness in several countries [4-6].”
COVID 19 Vaccine for Adolescents. Concern about Myocarditis and Pericarditis
Calcaterra, G., Mehta, J. L., GREGORIO, C. D., Butera, G., Neroni, P., Fanos, V., & Bassareo, P. P. (2021) · Pediatric Reports · doi:10.3390/pediatric13030061 · Cited by 24
“vaccines undoubtedly saved many thousands of lives [6].”
BackgroundEx vivo and in vivo suppression of SARS-CoV-2 with combinatorial AAV/RNAi expression vectors
Becker, J., Stanifer, M. L., Leist, S. R., Stolp, B., Maiakovska, O., West, A., Wiedtke, E., Börner, K., Ghanem, A., Ambiel, I., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.024 · Cited by 25
Considerations for Establishing Successful Coronavirus Disease Vaccination Programs in Africa
Williams, V., Edem, B. E., Calnan, M., Otwombe, K. N., & Okeahalam, C. C. (2021) · Emerging infectious diseases · doi:10.3201/eid2708.203870 · Cited by 25
Systemic sclerosis in the time of COVID-19
Hoffmann‐Vold, A., Distler, O., Bruni, C., Denton, C. P., de Vries-Bouwstra, J. K., Matucci‐Cerinic, M., Vonk, M. C., & Gabrielli, A. (2022) · The Lancet Rheumatology · doi:10.1016/s2665-9913(22)00130-8 · Cited by 31
Zhu, J., Tao, P., Chopra, A. K., & Rao, V. B. (2024) · Annual Review of Virology · doi:10.1146/annurev-virology-111821-111145 · Cited by 27
Tut, G., Lancaster, T., Krutikov, M., Sylla, P., Bone, D., Spalkova, E., Bentley, C., Amin, U., Jadir, A., Hulme, S., et al. (2023) · Nature Aging · doi:10.1038/s43587-022-00328-3 · Cited by 31
(2022) · doi:10.1101/2022.03.30.22273193 · Cited by 24
“Interval between symptoms onset and RTPCR testing, median (p25-p75), days 3 [2, 5] 3 [2, 5] 3 [2, 4] 3 [1, 4] Hospitalization or Death 2096 (16.”
BackgroundBirdsall, R. E., Han, D., DeLaney, K., Kowalczyk, A., Cojocaru, R., Lauber, M. A., & Huray, J. L. (2024) · Journal of Chromatography B · doi:10.1016/j.jchromb.2024.124005 · Cited by 26
Amatu, A., Pani, A., Patelli, G., Gagliardi, O. M., Loparco, M., Piscazzi, D., Cassingena, A., Tosi, F., Ghezzi, S., Campisi, D., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.12.006 · Cited by 25
Anti‐SARS‐CoV ‐2 vaccination strategy for pregnant women in Japan
Hayakawa, S., Komine‐Aizawa, S., Takada, K., Kimura, T., & Yamada, H. (2021) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.14748 · Cited by 26
Fukuda, H., Maeda, M., & Murata, F. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.03.059 · Cited by 21
“Pfizer–BioNTech’s BNT162b2 mRNA vaccine and Moderna’s mRNA-1273 vaccine showed efficacies of over 90% against symptomatic COVID19 in their respective trials [2,3].”
BackgroundGrothe, C., Steffen, F., & Bittner, S. (2021) · Journal of Central Nervous System Disease · doi:10.1177/11795735211060118 · Cited by 25
Lee, D. B., Kim, H., Jeong, J. H., Jang, U. S., Jang, Y., Roh, S., Jeon, H., Kim, E. J., Han, S. Y., Maeng, J. Y., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2208425120 · Cited by 26
PRACTICAL RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ITP DURING THE COVID-19 PANDEMIC
Rodeghiero, F. (2021) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2021.032 · Cited by 24
Qu, W., Wang, Z., Engelberg-Cook, E., Yan, D., Siddik, A. B., Bu, G., Allickson, J. G., Kubrova, E., Caplan, A. I., Hare, J. M., et al. (2022) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szac032 · Cited by 27
Sherman, A. C., Desjardins, M., Cheng, C., Bausk, B., Izaguirre, N., Zhou, G., Krauss, J., Tolan, N. V., Walt, D. R., Soiffer, R. J., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab930 · Cited by 26
“patients with hematological cancer [3, 4], leading to the hypo-”
BackgroundGorelik, Y., Anis, E., & Edelstein, M. L. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100234 · Cited by 25
Gazit, S., Mizrahi, B., Kalkstein, N., Neuberger, A., Peretz, A., Mizrahi-Reuveni, M., Ben-Tov, A., & Patalon, T. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab973 · Cited by 24
An immunostimulatory glycolipid that blocks SARS-CoV-2, RSV, and influenza infections in vivo
Tsuji, M., Nair, M. S., Masuda, K., Castagna, C., Chong, Z., Darling, T. L., Seehra, K., Hwang, Y., Ribeiro, Á. L., Ferreira, G. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39738-1 · Cited by 27
Pain in COVID-19: Quis est culpa?
Dobrovanov, O., Dmytrіiev, D., Prochotsky, A., Vidiscák, M., & Furková, K. (2022) · Electronic Journal of General Medicine · doi:10.29333/ejgm/12672 · Cited by 26
Impact of prior vaccination on clinical outcomes of patients with COVID-19
Seo, W. J., Kang, J., Kang, H. K., Park, S. H., Koo, H., Park, H. K., Lee, S.-S., Song, J. E., Kwak, Y. G., & Kang, J. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2069516 · Cited by 24
“344 Time from symptom onset to discharge, days 10 [9;11] 11 [10;14] <0.”
BackgroundInfluentialPerner, C., & Krüger, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.859703 · Cited by 29
Sex-related susceptibility in coronavirus disease 2019 (COVID-19): Proposed mechanisms
Aksoyalp, Z. Ş., & Samur, D. N. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174548 · Cited by 27
The findings of glucosyltransferase enzymes derived from oral streptococci
Hoshino, T., & Fujiwara, T. (2022) · Japanese Dental Science Review · doi:10.1016/j.jdsr.2022.10.003 · Cited by 20
Polymorphism of the HLA system and weak antibody response to BNT162b2 mRNA vaccine
Crocchiolo, R., Gallina, A. M., Pani, A., Campisi, D., Cento, V., Sacchi, N., Miotti, V., Gagliardi, O. M., D’Amico, F., Vismara, C., et al. (2022) · HLA · doi:10.1111/tan.14546 · Cited by 25
Morales-Zamora, G., Espinosa, O., Puertas, E., Fernández, J. C., Hernández, J., Zakzuk, V., Cepeda, M., Alvis‐Guzmán, N., Castañeda-Orjuela, C. A., & Paternina-Caicedo, Á. J. (2022) · Value in Health Regional Issues · doi:10.1016/j.vhri.2022.04.004 · Cited by 24
“We assumed the same efficiency and effectiveness reported in the medical trials of each vaccine.(4,5,7,8) The study is performed from the perspective of the third payer, the Colombia’s healthcare system.”
BackgroundMethodPark, S. H., Lim, S. Y., Kim, J. Y., Park, H., Lim, J. S., Bae, S., Kim, J., Jung, J., Kim, M. J., Chong, Y. P., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac239 · Cited by 28
“Although the development of several vaccines resulted in a temporary decline in the number of cases, hospitalizations, and deaths due to COVID-19 [2, 3], the emergence of variants including the SARS-CoV-2 Pango lineage B.”
BackgroundBreastfeeding Mother and Child Clinical Outcomes After COVID-19 Vaccination
Low, J. M., Lee, L. Y., Ng, Y. P. M., Zhong, Y., & Amin, Z. (2021) · Journal of Human Lactation · doi:10.1177/08903344211056522 · Cited by 26
Jawalagatti, V., Kirthika, P., Hewawaduge, C., Yang, M., Park, J.-Y., Oh, B., & Lee, J. H. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.042 · Cited by 24
“Two of the most widely used vaccines from Pfizer-BioNTech and Moderna demonstrated >94% efficacy in preventing COVID-19.(1,2) However, the emergence of novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants that exhibit increased ability to escape the vaccine-induced immunity has raised a great co…”
García‐Azorín, D., Baykan, B. B., Beghi, E., Doheim, M. F., Fernández‐de‐las‐Peñas, C., Gezegen, H., Guekht, A. B., Hoo, F. K., Santacatterina, M., Sejvar, J. J., et al. (2022) · Cephalalgia · doi:10.1177/03331024221099231 · Cited by 25
Wagner, R., Meißner, J., Grabski, E., Sun, Y., Vieths, S., & Hildt, E. (2021) · Allergy · doi:10.1111/all.14868 · Cited by 29
Jutel, M., Torres, M. J., Palomares, Ó., Akdiş, C. A., Eiwegger, T., Untersmayr, E., Barber, D., Zemelka‐Wiącek, M., Kosowska, A., Palmer, E., et al. (2022) · Allergy · doi:10.1111/all.15252 · Cited by 26
Rodríguez‐Espinosa, D., Montagud‐Marrahí, E., Cacho, J., Arana, C., Taurizano, N., Hermida, E., Risco-Zevallos, J. D., Casals, J., Rosario, A., Cuadrado‐Payán, E., et al. (2022) · Journal of Nephrology · doi:10.1007/s40620-022-01257-5 · Cited by 24
“The pivotal clinical trials of both mRNA-1273 and BNT162b2 show 94–95% protection against SARS-CoV-2 infections [15, 16].”
BackgroundD’Amelio, R., Asero, R., Cassatella, M. A., Laganà, B., Lunardi, C., Migliorini, P., Nisini, R., Parronchi, P., Quinti, I., Racanelli, V., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9091163 · Cited by 24
“Anti-COVID-19 mRNA vaccines, such as those developed by Pfizer/Biontech [28] and Moderna [29], are brand new and the first ones to be used on a large scale.”
BackgroundMethodInfluentialBatatinha, H., Baker, F. L., Smith, K. A., Zúñiga, T. M., Pedlar, C. R., Burgess, S. C., Katsanis, E., & Simpson, R. J. (2021) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00629.2021 · Cited by 27
Development of Bivalent mRNA Vaccines against SARS-CoV-2 Variants
Li, J., Liu, Q., Liu, J., Fang, Z., Luo, L., Li, S., Lei, Y., Li, Z., Jin, J., Xie, R., et al. (2022) · Vaccines · doi:10.3390/vaccines10111807 · Cited by 25
Significance of SARS-CoV-2 specific antibody testing during COVID-19 vaccine allocation
Fujimoto, A. B., Keskinocak, P., & Yildirim, I. B. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.06.067 · Cited by 25
Sacchi, M. C., Pelazza, C., Bertolotti, M., Agatea, L., Gaspari, P. D., Tamiazzo, S., Ielo, D., Stobbione, P., Grappiolo, M., Bolgeo, T., et al. (2023) · Autoimmunity · doi:10.1080/08916934.2023.2229072 · Cited by 24
Tsegay, K. B., Adeyemi, C. M., Gniffke, E. P., Sather, D. N., Walker, J. K., & Smith, S. E. P. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.685308 · Cited by 22
“While the success of rapidly developed vaccines offers hope to control the virus (Polack et al., 2020), treatments that improve disease outcomes are also critically needed.”
BackgroundPredictors of COVID-19 Vaccine Uptake in Healthcare Workers: A Cross-Sectional Study in Greece
Galanis, P., Moisoglou, I., Vraka, I. S., Siskou, O. C., Konstantakopoulou, O., Katsiroumpa, A., & Καϊτελίδου, Δ. (2021) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0000000000002463 · Cited by 25
Konstantinides, S. (2021) · European Respiratory Journal · doi:10.1183/13993003.01111-2021 · Cited by 25
“Consequently, since the COVID-19 vaccines mentioned above have been shown to effectively prevent symptomatic infection including hospital admissions and severe disease (8-10), the risk of COVID-19-related thrombosis should be expected to (almost) disappear in vaccinated individuals.”
BackgroundAnalysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants
Li, C., Guo, Y., Fang, Z., Zhang, H., Zhang, Y., & Chen, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.804945 · Cited by 25
Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge
Winkler, M. S., Skirecki, T., Brunkhorst, F. M., Cajander, S., Cavaillon, J., Ferrer, R., Flohé, S. B., García‐Salido, A., Giamarellos‐Bourboulis, E. J., Girardis, M., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103291 · Cited by 26
Qin, Y., Walters, A. A., Rouatbi, N., Wang, J. T.-W., Abdel‐Bar, H. M., & Al‐Jamal, K. T. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122158 · Cited by 28
ACTIVE SURVEILLANCE OF THE SPUTNIK V VACCINE IN HEALTH WORKERSPreprint
Pagotto, V. L., Ferloni, A., Soriano, M. M., Díaz, M., Golde, N. B., Gonzalez, M., Asprea, V., Staneloni, M. I., Vidal, G., Silveira, M., et al. (2021) · medRxiv · doi:10.1101/2021.02.03.21251071 · Cited by 75
Seow, J., Graham, C., Hallett, S. R., Lechmere, T., Maguire, T. J. A., Huettner, I., Cox, D., Khan, H., Pickering, S., Roberts, R., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110757 · Cited by 18
Chilblain lesions after COVID‐19 mRNA vaccine
Pileri, A., Guglielmo, A., Raone, B., et al. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20060 · Cited by 23
One-Stop Serum Assay Identifies COVID-19 Disease Severity and Vaccination Responses
Haddad, N. S., Nguyen, D. C., Kuruvilla, M. E., Morrison-Porter, A., Anam, F. A., Cashman, K. S., Ramonell, R. P., Kyu, S. Y., Saini, A. S., Cabrera-Mora, M., et al. (2021) · ImmunoHorizons · doi:10.4049/immunohorizons.2100011 · Cited by 29
“Blood samples were also collected from 18 subjects who had recently received their first or second immunizations with either the Pfizer (n = 16) (31) or Moderna (n = 2) (32) SARS-CoV-2 mRNA vaccines (Table I).”
BackgroundRay, S., Narayanan, A., Vesterbacka, J., Blennow, O., Chen, P., Gao, Y., Gabarrini, G., Ljunggren, H., Buggert, M., Manoharan, L., et al. (2023) · npj Biofilms and Microbiomes · doi:10.1038/s41522-023-00461-w · Cited by 25
Lipid nanoparticle screening in nonhuman primates with minimal loss of life
Zenhausern, R., Jang, B., Echeverri, E. S., Gentry, K., Calkins, R., Curran, E. H., Wood, J., Stammen, R. L., Loughrey, D., Chappa, P., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02711-y · Cited by 39
A multicenter study of ocular inflammation after COVID-19 vaccination
Yasaka, Y., Hasegawa, E., Keino, H., Usui, Y., Maruyama, K., Yamamoto, Y., Kaburaki, T., Iwata, D., Takeuchi, M., Kusuhara, S., et al. (2022) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-022-00962-9 · Cited by 24
Monitoring mRNA vaccine antigen expression in vivo using PET/CT
Blizard, G. S., Dwivedi, G., Pan, Y., Hou, C., Etersque, J. M., Said, H., Chevrier, A., Lavertu, M., Ni, H., Davis, B., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57446-w · Cited by 29
Unanticipated efficacy of SARS-CoV-2 vaccination in older adults
Pawelec, G., & McElhaney, J. E. (2021) · Immunity & Ageing · doi:10.1186/s12979-021-00219-y · Cited by 24
Abnormal Uterine Bleeding Among COVID-19 Vaccinated and Recovered Women: a National Survey
Issakov, G., Tzur, Y., Friedman, T., & Tzur, T. (2022) · Reproductive Sciences · doi:10.1007/s43032-022-01062-2 · Cited by 25
Sex-Differential and Non-specific Effects of Vaccines Over the Life Course
Clair, L. A. S., Chaulagain, S., Klein, S. L., Benn, C. S., & Flanagan, K. L. (2023) · Current topics in microbiology and immunology · doi:10.1007/978-3-031-35139-6_9 · Cited by 39
Forsgård, R. A., Rode, J., Lobenius-Palmér, K., Kamm, A., Patil, S., Tacken, M. G. J., Lentjes, M. A. H., Axelsson, J., Grompone, G., Montgomery, S., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2229938 · Cited by 25
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.